No longer trading

Acquired by Abbott Laboratories

The acquisition closed on March 23, 2026 (SEC 8-K 2.01). Its last closing price was on March 20, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from March 20, 2026. Source: SEC 8-K 2.01

EXAS

EXACT SCIENCES CORP EXAS

NasdaqLarge CapHealthcare

Final 13F Pro quality score

Final rank #1,098 of 2,777 · as of March 20, 2026TOP 50%

Why it scores 56Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$878.38M

Quarter to Dec 31

Net income

$-85.95M

Quarter to Dec 31

Free cash flow

$120.45M

Quarter to Dec 31

Operating margin

-9.4%

Quarter to Dec 31

Top Institutional Holders

as of Q1 2026
$11.70M total
Alpine Global Management, LLC
$6.97M-99.9%
K2 PRINCIPAL FUND, L.P.
$4.26M0.0%
DNCA FINANCE
$467.0K0.0%
Steward Partners Investment Advisory, LLC
$4.2K0.0%
Erste Asset Management GmbH
$0New
See all 5 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q4 2025
EDGAR

Net Income

Q4 2025
EDGAR

EPS (Diluted)

Q4 2025
EDGAR

Operating Margin

Q4 2025
EDGAR

ROIC

Q4 2025
EDGAR

Free Cash Flow

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/EXAS

Earnings Per Share

13fpro.ai/company/EXAS

Loading ratio trend…

EXAS key financials by period

Reported revenue, net income and operating margin by fiscal year, from EXACT SCIENCES CORP's annual filings on SEC EDGAR.

EXACT SCIENCES CORP reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$3.2B$-207.9M-6.3%
FY 2024$2.8B$-1.0B-38.0%
FY 2023$2.5B$-204.1M-8.6%
FY 2022$2.1B$-623.5M-28.5%
FY 2021$1.8B$-595.6M-48.4%
FY 2020$1.5B$-823.6M-51.5%
Source: EXAS filings on SEC EDGAR →

EXAS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in EXAS

14 transactions in EXAS reported by 2 members of Congress under the STOCK Act, most recent trade Mar 24, 2026. Reported transactions, not recommendations.

All Congress stock trades →

About EXACT SCIENCES CORP (EXAS): stock profile, AI score and financials

Acquired by Abbott Laboratories: EXACT SCIENCES CORP (EXAS) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on March 23, 2026 (SEC 8-K 2.01). Its last closing price was on March 20, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from March 20, 2026. EXACT SCIENCES CORP (EXAS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks EXAS using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q4 2025), EXACT SCIENCES CORP reports quarterly revenue of $878.4M, net income of $-86.0M, an operating margin of -9.4%. Top institutional holders of EXAS by reported 13-F value include Alpine Global Management, K2 PRINCIPAL FUND, L.P., DNCA FINANCE, based on the most recent SEC filings. EXAS trades on the Nasdaq exchange and files with the SEC under CIK 1124140. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EXAS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXACT SCIENCES CORP directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1124140 →